EARLY B LYMPHOCYTES IN MANCONTE PF; BOCCADORO M; PILERI A et al.1980; EXPERIENTIA; ISSN 0014-4754; CHE; DA. 1980; VOL. 36; NO 9; PP. 1124-1125; BIBL. 9 REF.Article

BIOLOGY OF THE HUMAN MYELOMA CELL POPULATION. II. CYTOKINETIC CHARACTERISTICSHULIN N; CONTE PF; PILERI A et al.1978; RIC. CLIN. LAB.; ITA; DA. 1978; VOL. 8; NO 1-2; PP. 49-55; BIBL. 21 REF.Article

Cell kinetics of multiple myelomaBOCCADORO, M; PILERI, A.Hematologic pathology. 1987, Vol 1, Num 3, pp 137-142, issn 0886-0238Article

Standard chemotherapy for myolomatosis : an area of great controversyBOCCADORO, M; PILERI, A.Hematology/oncology clinics of North America. 1992, Vol 6, Num 2, pp 371-382, issn 0889-8588Article

BREAKDOWN OF RNA AND PROTEIN SYNTHESIS TEMPLATE STABILITY IN PROLIFERATING AND NON PROLIFERATING HUMAN MYELOMA CELLS.PILERI A; CONTE PF; BOCCADORO M et al.1977; HAEMATOLOGICA; ITAL.; DA. 1977; VOL. 62; NO 5; PP. 559-561; BIBL. 12 REF.Article

ACTINOMYCIN BINDING CAPACITY IN HUMAN LEUKAEMIC LYMPHOID CELLS = POUVOIR DE FIXATION DE L'ACTINOMYCINE DES CELLULES LYMPHOIDES LEUCEMIQUES CHEZ L'HOMMEPILERI A; MASERA P; HULIN N et al.1972; ACTA HAEMATOL.; SUISSE; DA. 1972; VOL. 48; NO 2; PP. 89-97; BIBL. 2P.Serial Issue

BONE MARROW RETURN AND DIVISION OF CIRCULATING ACUTE LYMPHOBLASTIC LEUKAEMIA CELLS = LE RETOUR A LA MOELLE OSSEUSE ET LA DIVISION DE CELLULES CIRCULANTES DE LEUCEMIE LYMPHOBLASTIQUE AIGUETAROCCO RP; PILERI A; PONZONE A et al.1972; ACTA HAEMATOL.; SUISSE; DA. 1972; VOL. 47; NO 5; PP. 277-282; BIBL. 6 REF.Serial Issue

LYMPHOCYTE ACTINOMYCIN BINDING CAPACITY IN CHRONIC LYMPHOCYTIC LEUKAEMIA = CAPACITE DE FIXATION DE L'ACTINOMYCINE PAR LES LYMPHOCYTES DANS LA LEUCEMIE CHRONIQUE LYMPHOCYTAIREMASERA P; PILERI A; BRACHET J et al.1972; EXPERIENTIA; SUISSE; DA. 1972; VOL. 28; NO 12; PP. 1484; ABS. ALLEM.; BIBL. 6 REF.Serial Issue

BIOLOGY OF THE HUMAN MYELOMA CELL POPULATION. I. MACROMOLECULAR CHARACTERISTICSHULIN N; BOCCADORO M; MASERA P et al.1978; RIC. CLIN. LAB.; ITA; DA. 1978; VOL. 8; NO 1-2; PP. 39-48; BIBL. 18 REF.Article

Growth advantage of chronic myeloid leukemia CFU-GM in vitro : survival to growth factor deprivation, possibly related to autocrine stimulation, is a more common feature than hypersensitivity to GM-CSF/IL3 and is efficiently counteracted by retinoids ± α-interferonFERRERO, D; FOLI, C; GIARETTA, F et al.Leukemia. 2001, Vol 15, Num 3, pp 422-429, issn 0887-6924Conference Paper

Dose-intensive melphalan with stem cell support (CM regimen) is effective and well tolerated in elderly myeloma patientsPALUMBO, A; TRIOLO, S; MARMONT, F et al.Haematologica (Roma). 2000, Vol 85, Num 5, pp 508-513, issn 0390-6078Article

Dose-intensive melphalan with stem cell support (MEL100) is superior to standard treatment in elderly myeloma patientsPALUMBO, A; TRIOLO, S; ARGENTINO, C et al.Blood. 1999, Vol 94, Num 4, pp 1248-1253, issn 0006-4971Article

High-dose chemotherapy and autologous bone marrow transplantation compared with MACOP-B in aggressive B-cell lymphomaGIANNI, A. M; BREGNI, M; VALAGUSSA, P et al.The New England journal of medicine. 1997, Vol 336, Num 18, pp 1290-1297, issn 0028-4793Article

Diagnosis, prognosis, and standard treatment of multiple myelomaBOCCADORO, M; PILERI, A.Hematology/oncology clinics of North America. 1997, Vol 11, Num 1, pp 111-131, issn 0889-8588Article

CD3-induced T-cell activation in the bone marrow of myeloma patients : major role of CD4⁺ cellsBIANCHI, A; MONTACCHINI, L; BARRAL, P et al.British journal of haematology. 1995, Vol 90, Num 3, pp 625-632, issn 0007-1048Article

Haematological support of high-dose sequential chemotherapy : clinical evidence for reduction of toxicity and high response rates in poor risk lymphomasTARELLA, C; GAVAROTTI, P; CARACCIOLO, D et al.Annals of oncology. 1995, Vol 6, Num 4, pp 3-8, issn 0923-7534, SUPArticle

Selection and characterization of early hematopoietic progenitors using an anti-CD71/S06 immunotoxinBENEDETTI, G; BONDESAN, P; CARACCIOLO, D et al.Experimental hematology. 1994, Vol 22, Num 2, pp 166-173, issn 0301-472XArticle

High-dose sequential chemoradiotherapy, a widely applicable regimen, confers survival benefit to patients with high-risk multiple myelomaGIANNI, A. M; TARELLA, C; PILERI, A et al.Journal of clinical oncology. 1994, Vol 12, Num 3, pp 503-509, issn 0732-183XArticle

C-reactive protein and β-2 microglobulin produce a simple and powerful myeloma staging systemBATAILLE, R; BOCCADORO, M; KLEIN, B et al.Blood. 1992, Vol 80, Num 3, pp 733-737, issn 0006-4971Article

Durable and complete hematopoietic reconstitution after autografting of rhGM-CSF exposed peripheral blood progenitor cellsGIANNI, A. M; TARELLA, C; SIENA, S et al.Bone marrow transplantation (Basingstoke). 1990, Vol 6, Num 2, pp 143-145, issn 0268-3369, 3 p.Article

Multiple myeloma : increased circulating lymphocytes carrying plasma cell-associated antigens as and indicator of poor survivalOMEDE, P; BOCCADORO, M; GALLONE, G et al.Blood. 1990, Vol 76, Num 7, pp 1375-1379, issn 0006-4971Article

Emergence of activated lymphocytes in CD4 and CD8 subpopulations of multiple myeloma: correlation with the expansion of suppressor T-cells (CD8+OKM1+) and ecto-5' nucleotidase deficiencyMASSAIA, M; DIANZANI, U; PIOPPO, P et al.Journal of clinical & laboratory immunology. 1988, Vol 26, Num 2, pp 89-95, issn 0141-2760Article

Immunologic and virologic findings in hemophiliacs do not correlate with ecto-5' nucleotidase activity of peripheral blood lymphocytes. A difference with homosexual memMASSAIA, M; PIOPPO, P; DIANZANI, U et al.European journal of haematology. 1987, Vol 38, Num 4, pp 310-314, issn 0902-4441Article

Differential expression of ecto-5' nucleotidase activity by functionally and phenotypically distinct subpopulations of human Leu-2⁺/T8⁺ lymphocytesDIANZANI, U; MASSAIA, M; PILERI, A et al.The Journal of immunology (1950). 1986, Vol 137, Num 2, pp 484-489, issn 0022-1767Article

Reactive plasmacytosis. Case report and review of the literatureGAVAROTTI, P; BOCCADORO, M; REDOGLIA, V et al.Acta haematologica. 1985, Vol 73, Num 2, pp 108-110, issn 0001-5792Article